scholarly journals Dual-Block Elastic Stain Significantly Increasing Visceral Pleural Invasion(VPI) Positivity and Analysis of Potential Predictors of VPI in Peripheral Non-Small Cell Lung Cancer

2021 ◽  
Author(s):  
Shaoling Li ◽  
Yan Huang ◽  
Liping Zhang ◽  
Zhengwei Dong ◽  
Wei Wu ◽  
...  
Keyword(s):  
Tumor Tissue ◽  
Small Cell ◽  
Block Group ◽  
Small Cell Lung ◽  
Pleural Invasion ◽  
Significant Difference ◽  
Single Block ◽  
Elastic Stain ◽  
Visceral Pleural Invasion ◽  
Nsclc Patients

Abstract Background: Visceral pleural invasion (VPI) is a critical component in the staging of peripheral non–small cell lung carcinoma (NSCLC). Single tumor tissue block for elastic stain is conducive to identifying pleural invasion in routine pathologic examination. We aim to investigate whether dual-block elastic stain increase VPI positivity compared with single-block elastic stain, further analyze the potential predictors of VPI status.Methods: Resected 8419 consecutive peripheral NSCLC cases including tumor size≤3cm 6008 patients were retrospectively reviewed. Total cases were divided into a cohort using one tumor tissue paraffin block (single-block group, n=5184) and a cohort using dual tumor tissue paraffin blocks (dual-block group, n=3235) for elastic stain. Each case was performed with Victoria-blue van Gieson staining to assess VPI status. The clinicopathologic features of patients were collected from the electronic medical record system.Results: The overall incidence of VPI was 12.4% (1047/8419) in peripheral NSCLC patients. The VPI positivity detected by dual-block elastic stain was significantly higher than that by single-block elastic stain (17.7% (573/3235) v.s. 9.1% (474/5184), P＜0.001). The presence of VPI in T1 ≤3cm patients detected by single and dual block elastic stain was 6.3% (235/3730) and 12.0% (273/2278), respectively (P＜0.001). Therefore, 5.7% T1 patients (stage IA) are additionally upstaged to T2a (stage IB) by dual block elastic stain. But the incidence of VPI in pT2a patients had no significant difference between single-block group and dual-block group (16.8% vs 17.1%, P=0.916). The lymphovascular invasion, lymph node metastasis, poor differentiated carcinomas and the presence of STAS status could be well significant predictors of VPI (P＜0.001). Area under the ROC curve of adenocarcinoma morphology was 0.263 for lepidic pattern, 0.544 for acinar and papillary pattern, and 0.720 for micropapillary and solid pattern in predicting invasion of pleura.Conclusion: Our results indicated that using dual-block elastic stain identify more VPI positive T1 NSCLC patients who are upstaged to T2a and could benefit from optimal management after post-operation. The application of dual-block elastic stain is an efficient and practical method to detect VPI, especially for patients with high-risk prognostic factors.

scholarly journals Does Visceral Pleural Invasion Affect Prognosis in Stage I Non-Small Cell Lung Cancer?

2015 ◽  
Vol 100 (5) ◽  
pp. 1977 ◽  
Author(s):  
Alessandro Baisi ◽  
Federico Raveglia ◽  
Matilde De Simone ◽  
Ugo Cioffi
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Pleural Invasion ◽  
Visceral Pleural Invasion

scholarly journals Effect of visceral pleural invasion on the prognosis of patients with lymph node negative non-small cell lung cancer

2017 ◽  
Vol 8 (2) ◽  
pp. 97-105 ◽  
Author(s):  
Dan Tian ◽  
Yuquan Pei ◽  
Qingfeng Zheng ◽  
Jianzhi Zhang ◽  
Shaolei Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Negative ◽  
Pleural Invasion ◽  
Visceral Pleural Invasion

Potential role of serum proteome in predicting immune-related adverse events from immune checkpoint inhibitors in non-small cell lung cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21218-e21218
Author(s):  
Leeseul Kim ◽  
Young Kwang Chae ◽  
Chan Mi Jung ◽  
Emma Yu ◽  
Alice Daeun Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adverse Events ◽  
Small Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Significant Difference ◽  
Nsclc Patients

e21218 Background: Early recognition of immune-related adverse events (irAEs) of immune checkpoint inhibitors(ICI) is important. Circulating proteome reflects host response to diseases and is being explored as a marker for response to immunotherapy. We previously have reported that a serum-based proteomics test, Primary Immune Response (PIR) demonstrated a trend that PIR-sensitive patients are more likely to tolerate ICI treatment longer without developing irAEs in non-small cell lung cancer (NSCLC) patients. The VeriStrat test is another serum-based proteomic assay, which was reported to be predictive of survival outcomes for all treatment regimens and lines of therapy including ICI in NSCLC. We explored the associations between the VeriStrat test and developing irAEs in NSCLC patients treated with ICI. Methods: Data of 70 consented NSCLC patients treated with any regimens and lines of therapy including ICI were collected. Samples were grouped into either VeriStrat ‘Good’(VS-G) or VeriStrat ‘Poor’(VS-P). We analyzed the durations from the immunotherapy initiation to each episode of irAE and each irAE above grade 2 using log-rank test. IrAEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Results: Among the 70 patients, 18 patients (25%) experienced one or more irAEs. There was no significant difference in ‘Time to first irAE’ between VS-G and VS-P (p = 0.72, HR = 0.82, 95% CI = 0.29-2.32). Among 48 VS-G patients, 12(25%) had one or more irAE and 5(10%)had irAE graded over 2. Among 22 VS-P patients, 6(27%) had one or more irAE and 2(9%) had irAE graded over 2. There was no significant difference between VS-G and VS-P groups in the development of irAE and irAE graded over 2. Conclusions: There was no statistically significant association between the VeriStrat test and the development of irAEs. Further studies are warranted to investigate proper serum based proteomic assay to predict the development of irAE.

Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy

2015 ◽  
Vol 30 (4) ◽  
pp. 374-381
Author(s):  
Fadi Najjar ◽  
Ghassan Al-Massarani ◽  
Israa Banat ◽  
Moosheer Alammar
Keyword(s):  
Advanced Nsclc ◽  
Tumor Response ◽  
Small Cell ◽  
Percentage Change ◽  
Circulating Endothelial Cells ◽  
Small Cell Lung ◽  
First Line ◽  
Significant Difference ◽  
Nsclc Patients ◽  
Line Chemotherapy

Background Circulating endothelial cells (CECs) reflect the neovascularization in the tumor mass. We therefore investigated the potential role of CEC kinetics after first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Methods Peripheral blood samples were obtained from 45 healthy subjects and 51 naïve patients with advanced NSCLC. Quantification of CD146+ CECs was performed using immunomagnetic separation (IMS). Results Pretreatment and posttreatment CEC levels in NSCLC patients were significantly higher than in healthy subjects (p<0.0001). An objective response was achieved after chemotherapy with partial response (PR) or stable disease (SD) in 26 patients, whereas the remaining 25 patients had progressive disease (PD). Baseline CEC levels were significantly higher in PR/SD patients than in PD patients (p = 0.039). After chemotherapy, CEC count significantly decreased in PR/SD patients (p = 0.014) and increased in patients with PD (p = 0.019). Moreover, there was a significant difference in the percentage change of CEC counts between the 2 groups (p = 0.0016). No significant difference in the median progression-free survival and overall survival (OS) was observed between patients with high baseline CEC counts and those with low baseline CEC levels. However, patients with high percentage change in CEC count had longer OS than those with low percentage change after chemotherapy (p = 0.05). Conclusions Changes in CEC counts after chemotherapy reflect tumor response in advanced NSCLC patients. Moreover, high percentage changes in CEC counts after chemotherapy may predict longer OS in advanced NSCLC. High baseline CEC levels might be an indicator of tumor response in advanced NSCLC patients after first-line chemotherapy.

scholarly journals Impact of visceral pleural invasion on the association of extent of lymphadenectomy and survival in stage I non-small cell lung cancer

2019 ◽  
Vol 8 (2) ◽  
pp. 669-678 ◽  
Author(s):  
Yang Wo ◽  
Yandong Zhao ◽  
Tong Qiu ◽  
Shicheng Li ◽  
Yuanyong Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Pleural Invasion ◽  
Visceral Pleural Invasion

scholarly journals P1.17-10 Prediction of Visceral Pleural Invasion in c-N0 Non-Small Cell Lung Cancer

2019 ◽  
Vol 14 (10) ◽  
pp. S611
Author(s):  
S. Okada ◽  
A. Hattori ◽  
T. Matsunaga ◽  
K. Takamochi ◽  
S. Oh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pleural Invasion ◽  
Visceral Pleural Invasion

Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e18092-e18092
Author(s):  
Hyun Chang ◽  
Xianglan Zhang ◽  
Da Rae Kim ◽  
Gun Min Kim ◽  
Se Hyun Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Small Cell Lung Cancer ◽  
Tumor Tissue ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Nsclc Patients ◽  
Egfr Tkis

e18092 Background: We performed this study to investigate whether activation of cMET is associated with sensitivity to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients. Methods: This retrospective study included 69 NSCLC patients with available tumor tissue, treatment response and survival data. cMET and hepatocyte growth factor (HGF) status was evaluated by immunohistochemistry. Results: A positive cMET, cMET[pY1003], cMET[pY1234/1235] and HGF were identified in 89%, 44%, 20% and 89% of cases, respectively. Positive cMET[pY1003] expression was associated with better objective response rate (OR) and clinical benefit rate (CBR) (OR, P = 0.033 and CBR, P = 0.039). Positive cMET[pY1234/1235] was significantly associated with a longer overall survival (OS) (P = 0.012) and time-to progression (TTP) (P = 0.031). Multivariable model confirmed that cMET[pY1234/235]-positive patients had a significant reduction in the risk of death and disease progression than cMET[pY1234/1235] –negative patients [OS; hazard ratio(HR)=0.29, P = 0.008 and TTP; HR=0.43; P=0.024] Conclusions: cMET expression in tumor tissue could be useful for predicting the clinical outcome of EGFR-TKIs treatment. Our results suggest that cMET expression in tumor tissue could be used to refine the selection of NSCLC patients expected to benefit from EGFR-TKIs treatment.

Predictive biomarker of response to anti-PD-1 treatment in non-small cell lung cancer patients.

2018 ◽  
Vol 36 (5_suppl) ◽  
pp. 148-148
Author(s):  
Xuan Zheng ◽  
Yi Hu ◽  
Junxun Ma ◽  
Fan Zhang ◽  
Danyang Sun ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Predictive Biomarker ◽  
Small Cell ◽  
Response Evaluation ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Significant Difference ◽  
Nsclc Patients

148 Background: PD-1 inhibitors have shown significant clinical activity in different cancer types. However, responses in pts with NSCLC are variable, and insights are needed to identify a predictive biomarker of response with greater diagnostic accuracy. Here we tested the hypothesis tha tserum TNF-a level is predictive of response to anti-PD-1 treatment. Methods: NSCLC patients treated with nivolumab or pembrolizumab were studied. Pts received nivolumab (3mg/kg, q2w) or pembrolizumab ( 2mg/kg, q3w). Pts on anti-PD1 were classified as either responders (R) deriving clinical benefit (with SD, PR, CR) or non-responders (NR) not deriving clinical benefit (PD) based on RECIST criteria.Serum was collected at baseline; at 2-3 weeks after the first dose (early stage); and at the time of response evaluation. Serum TNF-a levels were determined by Luminex kit. Changes in serum TNF-a levels and their strength of association with response were compared with Non-parametric Analysis. Results: Evaluable plasma samples were collected from twenty-one NSCLC patients treated with nivolumab or pembrolizumab. There was no significant difference in baseline serum TNF-a levels in responders (n = 15) vs non-responders (n = 6). Between baseline and early stage ,serum TNF-a levels significantly increased in responders (P = 0.010), while in non-responders, no significant change was found. High early change rate of serum TNF-a levels ( > 50%) was observed only in responders(n = 7).At early stage, responders had significantly higher serum TNF-a levels than non-responders(P = 0.008). We found no significant difference in serum TNF-a levels at the time of response evaluation. Conclusions: Early changes in serum TNF-a levels and high serum TNF-a levels at early stage in non-small cell lung cancer patients correlate to response to anti-PD-1 treatment.

Sign in / Sign up

Export Citation Format

Share Document